Comparative Pharmacology
Head-to-head clinical analysis: CO GESIC versus Q GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO GESIC versus Q GESIC.
CO-GESIC vs Q-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-GESIC (hydrocodone/acetaminophen) is a combination analgesic. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and elevating pain threshold.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
1-2 tablets (hydrocodone 5 mg/acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Primarily renal (60–70% as unchanged drug and metabolites); minor biliary/fecal excretion (<5%).
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination